PH26419A - Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxyic acid - Google Patents

Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxyic acid Download PDF

Info

Publication number: PH26419A
Authority: PH; Philippines
Prior art keywords: acid; solution according; infusion solution; active compound; mols
Prior art date: 1985-10-24

Application number

PH34403A

Other languages

English (en)

Inventor

Robert Frank Lammens

Original Assignee

Bayer Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-10-24

Filing date

1986-10-23

Publication date

1992-07-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6284294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH26419(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1986-10-23 Application filed by Bayer Ag filed Critical Bayer Ag

1992-07-15 Publication of PH26419A publication Critical patent/PH26419A/en

Links

239000003978 infusion fluid Substances 0.000 title claims description 47
239000002253 acid Substances 0.000 title claims description 35
150000001875 compounds Chemical class 0.000 claims description 51
JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 45
239000000243 solution Substances 0.000 claims description 32
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 22
239000004310 lactic acid Substances 0.000 claims description 22
235000014655 lactic acid Nutrition 0.000 claims description 22
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 16
229960000448 lactic acid Drugs 0.000 claims description 14
150000007513 acids Chemical class 0.000 claims description 11
239000011780 sodium chloride Substances 0.000 claims description 11
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
239000007864 aqueous solution Substances 0.000 claims description 5
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 4
RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 claims description 4
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 4
IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 claims description 4
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 4
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims description 4
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 4
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 claims description 2
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 claims description 2
RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-UWTATZPHSA-N L-Aspartic acid Natural products OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 claims description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 2
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
229960000583 acetic acid Drugs 0.000 claims description 2
IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 claims description 2
IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims description 2
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims description 2
229910000147 aluminium phosphate Inorganic materials 0.000 claims description 2
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 2
235000010323 ascorbic acid Nutrition 0.000 claims description 2
239000011668 ascorbic acid Substances 0.000 claims description 2
229960005070 ascorbic acid Drugs 0.000 claims description 2
229960005261 aspartic acid Drugs 0.000 claims description 2
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 2
239000001530 fumaric acid Substances 0.000 claims description 2
239000000174 gluconic acid Substances 0.000 claims description 2
235000012208 gluconic acid Nutrition 0.000 claims description 2
229940097043 glucuronic acid Drugs 0.000 claims description 2
239000004220 glutamic acid Substances 0.000 claims description 2
235000013922 glutamic acid Nutrition 0.000 claims description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
239000011976 maleic acid Substances 0.000 claims description 2
239000001630 malic acid Substances 0.000 claims description 2
235000011090 malic acid Nutrition 0.000 claims description 2
229940099690 malic acid Drugs 0.000 claims description 2
229940074355 nitric acid Drugs 0.000 claims description 2
229910017604 nitric acid Inorganic materials 0.000 claims description 2
229960004838 phosphoric acid Drugs 0.000 claims description 2
235000019260 propionic acid Nutrition 0.000 claims description 2
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims description 2
239000011975 tartaric acid Substances 0.000 claims description 2
235000002906 tartaric acid Nutrition 0.000 claims description 2
235000002639 sodium chloride Nutrition 0.000 description 22
150000003839 salts Chemical class 0.000 description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
238000004090 dissolution Methods 0.000 description 8
208000015181 infectious disease Diseases 0.000 description 8
244000052769 pathogen Species 0.000 description 8
-1 alkaline earth metal salt Chemical class 0.000 description 6
MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 6
238000001802 infusion Methods 0.000 description 6
238000000034 method Methods 0.000 description 6
239000012141 concentrate Substances 0.000 description 5
235000008504 concentrate Nutrition 0.000 description 5
235000011167 hydrochloric acid Nutrition 0.000 description 5
229960000443 hydrochloric acid Drugs 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000126 substance Substances 0.000 description 5
206010039438 Salmonella Infections Diseases 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000003814 drug Substances 0.000 description 4
206010039447 salmonellosis Diseases 0.000 description 4
239000000725 suspension Substances 0.000 description 4
201000004813 Bronchopneumonia Diseases 0.000 description 3
206010012735 Diarrhoea Diseases 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000000844 anti-bacterial effect Effects 0.000 description 3
150000001720 carbohydrates Chemical class 0.000 description 3
235000014633 carbohydrates Nutrition 0.000 description 3
229960003405 ciprofloxacin Drugs 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
238000004108 freeze drying Methods 0.000 description 3
208000004396 mastitis Diseases 0.000 description 3
244000005700 microbiome Species 0.000 description 3
206010034674 peritonitis Diseases 0.000 description 3
230000004224 protection Effects 0.000 description 3
230000009885 systemic effect Effects 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
241000588921 Enterobacteriaceae Species 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
206010048461 Genital infection Diseases 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
208000005141 Otitis Diseases 0.000 description 2
206010034107 Pasteurella infections Diseases 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
241000607734 Yersinia <bacteria> Species 0.000 description 2
WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
229910052783 alkali metal Inorganic materials 0.000 description 2
150000001340 alkali metals Chemical class 0.000 description 2
229910052784 alkaline earth metal Inorganic materials 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
239000002585 base Substances 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
230000000875 corresponding effect Effects 0.000 description 2
238000002425 crystallisation Methods 0.000 description 2
230000008025 crystallization Effects 0.000 description 2
208000001848 dysentery Diseases 0.000 description 2
208000019258 ear infection Diseases 0.000 description 2
239000011521 glass Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
150000004677 hydrates Chemical class 0.000 description 2
201000005115 pasteurellosis Diseases 0.000 description 2
239000004033 plastic Substances 0.000 description 2
201000007094 prostatitis Diseases 0.000 description 2
238000001228 spectrum Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
206010060921 Abdominal abscess Diseases 0.000 description 1
241000589291 Acinetobacter Species 0.000 description 1
206010003011 Appendicitis Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
208000035143 Bacterial infection Diseases 0.000 description 1
241000606124 Bacteroides fragilis Species 0.000 description 1
206010005940 Bone and joint infections Diseases 0.000 description 1
241000589562 Brucella Species 0.000 description 1
241000589876 Campylobacter Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
206010007882 Cellulitis Diseases 0.000 description 1
229930186147 Cephalosporin Natural products 0.000 description 1
241000588923 Citrobacter Species 0.000 description 1
241000193403 Clostridium Species 0.000 description 1
208000003322 Coinfection Diseases 0.000 description 1
241000272201 Columbiformes Species 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
201000004624 Dermatitis Diseases 0.000 description 1
206010014561 Emphysema Diseases 0.000 description 1
208000004145 Endometritis Diseases 0.000 description 1
208000004232 Enteritis Diseases 0.000 description 1
241000588914 Enterobacter Species 0.000 description 1
241000186811 Erysipelothrix Species 0.000 description 1
208000001860 Eye Infections Diseases 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
239000005715 Fructose Substances 0.000 description 1
229930091371 Fructose Natural products 0.000 description 1
RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010017964 Gastrointestinal infection Diseases 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000588731 Hafnia Species 0.000 description 1
102100029054 Homeobox protein notochord Human genes 0.000 description 1
101000634521 Homo sapiens Homeobox protein notochord Proteins 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
241000186781 Listeria Species 0.000 description 1
206010024652 Liver abscess Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
208000010315 Mastoiditis Diseases 0.000 description 1
201000009906 Meningitis Diseases 0.000 description 1
241000219470 Mirabilis Species 0.000 description 1
241001430197 Mollicutes Species 0.000 description 1
101100128278 Mus musculus Lins1 gene Proteins 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
241000204048 Mycoplasma hominis Species 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000187654 Nocardia Species 0.000 description 1
RSPISYXLHRIGJD-UHFFFAOYSA-N OOOO Chemical compound OOOO RSPISYXLHRIGJD-UHFFFAOYSA-N 0.000 description 1
206010031252 Osteomyelitis Diseases 0.000 description 1
241000606860 Pasteurella Species 0.000 description 1
241001494479 Pecora Species 0.000 description 1
241000206591 Peptococcus Species 0.000 description 1
241000191992 Peptostreptococcus Species 0.000 description 1
201000007100 Pharyngitis Diseases 0.000 description 1
241000286209 Phasianidae Species 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000588768 Providencia Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
206010037151 Psittacosis Diseases 0.000 description 1
208000020264 Puerperal Infection Diseases 0.000 description 1
206010037596 Pyelonephritis Diseases 0.000 description 1
241000606701 Rickettsia Species 0.000 description 1
239000008156 Ringer's lactate solution Substances 0.000 description 1
241000282849 Ruminantia Species 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
208000007893 Salpingitis Diseases 0.000 description 1
241000607720 Serratia Species 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000295644 Staphylococcaceae Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
208000033809 Suppuration Diseases 0.000 description 1
208000031650 Surgical Wound Infection Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000589886 Treponema Species 0.000 description 1
208000037386 Typhoid Diseases 0.000 description 1
206010046793 Uterine inflammation Diseases 0.000 description 1
206010048038 Wound infection Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
206010000269 abscess Diseases 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000001154 acute effect Effects 0.000 description 1
239000001361 adipic acid Substances 0.000 description 1
235000011037 adipic acid Nutrition 0.000 description 1
229960000250 adipic acid Drugs 0.000 description 1
230000001668 ameliorated effect Effects 0.000 description 1
229940024606 amino acid Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
208000022362 bacterial infectious disease Diseases 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
229940124587 cephalosporin Drugs 0.000 description 1
150000001780 cephalosporins Chemical class 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
208000003167 cholangitis Diseases 0.000 description 1
201000001352 cholecystitis Diseases 0.000 description 1
239000008139 complexing agent Substances 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000012611 container material Substances 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
201000003146 cystitis Diseases 0.000 description 1
206010062952 diffuse panbronchiolitis Diseases 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
206010014665 endocarditis Diseases 0.000 description 1
201000010063 epididymitis Diseases 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
208000011323 eye infectious disease Diseases 0.000 description 1
239000012530 fluid Substances 0.000 description 1
239000008103 glucose Substances 0.000 description 1
235000001727 glucose Nutrition 0.000 description 1
229960004275 glycolic acid Drugs 0.000 description 1
CJNBYAVZURUTKZ-UHFFFAOYSA-N hafnium(IV) oxide Inorganic materials O=[Hf]=O CJNBYAVZURUTKZ-UHFFFAOYSA-N 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
238000002156 mixing Methods 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
201000000901 ornithosis Diseases 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
239000005022 packaging material Substances 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
235000011007 phosphoric acid Nutrition 0.000 description 1
244000144977 poultry Species 0.000 description 1
238000012545 processing Methods 0.000 description 1
238000011321 prophylaxis Methods 0.000 description 1
239000011814 protection agent Substances 0.000 description 1
230000000384 rearing effect Effects 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
238000000926 separation method Methods 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
206010040872 skin infection Diseases 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
235000010356 sorbitol Nutrition 0.000 description 1
229960002920 sorbitol Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
150000003456 sulfonamides Chemical class 0.000 description 1
239000001117 sulphuric acid Substances 0.000 description 1
235000011149 sulphuric acid Nutrition 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940040944 tetracyclines Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
201000008297 typhoid fever Diseases 0.000 description 1
241001148471 unidentified anaerobic bacterium Species 0.000 description 1
208000000143 urethritis Diseases 0.000 description 1
208000019206 urinary tract infection Diseases 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Dermatology (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

PH34403A 1985-10-24 1986-10-23 Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxyic acid PH26419A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE19853537761 DE3537761A1 (de)	1985-10-24	1985-10-24	Infusionsloesungen der 1-cyclopropyl-6-fluor-1,4-dihydro-4-oxo-7- (1-piperazinyl)-chinolin-3-carbonsaeure

Publications (1)

Publication Number	Publication Date
PH26419A true PH26419A (en)	1992-07-15

Family

ID=6284294

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH34403A PH26419A (en)	1985-10-24	1986-10-23	Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxyic acid

Country Status (27)

Country	Link
US (1)	US4957922A (ja)
EP (1)	EP0219784B1 (ja)
JP (1)	JPH0714879B2 (ja)
KR (1)	KR940002664B1 (ja)
AR (1)	AR244085A1 (ja)
AT (1)	ATE59003T1 (ja)
AU (1)	AU571796B2 (ja)
CA (1)	CA1282006C (ja)
CY (1)	CY1729A (ja)
DD (1)	DD252125A5 (ja)
DE (2)	DE3537761A1 (ja)
DK (1)	DK175494B1 (ja)
ES (1)	ES2021571B3 (ja)
FI (1)	FI84555C (ja)
GR (1)	GR3002544T3 (ja)
HK (1)	HK115593A (ja)
HU (1)	HUT42952A (ja)
IE (1)	IE59385B1 (ja)
IL (1)	IL80380A (ja)
NO (1)	NO864022L (ja)
NZ (1)	NZ218016A (ja)
PH (1)	PH26419A (ja)
PL (1)	PL152336B1 (ja)
PT (1)	PT83588B (ja)
SU (1)	SU1487801A3 (ja)
UA (1)	UA8033A1 (ja)
ZA (1)	ZA868057B (ja)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5281596A (en) *	1986-02-19	1994-01-25	Bayer Aktiengesellschaft	Antibacterial drugs for fish
JPS62192321A (ja) *	1986-02-19	1987-08-22	Bayer Japan Kk	魚類用抗菌剤
FI883337L (fi) *	1987-07-16	1989-01-17	Bristol Myers Co	Icke-vattenloesningar av doxorubicinhydroklorin.
FI883338A7 (fi) *	1987-07-16	1989-01-17	Bristol Myers Squibb Co	Doksorubisiinihydrokloridin vesiliuoksia
JPH01175935A (ja) *	1987-12-28	1989-07-12	Kyorin Pharmaceut Co Ltd	凍結乾燥注射剤
DE3902079A1 (de) *	1988-04-15	1989-10-26	Bayer Ag	I.m. injektionsformen von gyrase-inhibitoren
NZ232740A (en) *	1989-04-20	1992-06-25	Riker Laboratories Inc	Solution for parenteral administration comprising a 1h-imidazo(4,5-c) quinolin-4-amine derivative, an acid and a tonicity adjuster
FR2655545B1 (fr) *	1989-12-11	1994-06-10	Rhone Poulenc Sante	Nouvelle application therapeutique des derives des fluoroquinolones.
US6300361B1 (en) *	1990-07-25	2001-10-09	Novartis Ag	Stabilized pharmaceutical compositions comprising acid donors
FR2681863B1 (fr) *	1991-09-27	1995-02-03	Rhone Dpc Europ	Solution de sparfloxacine sa preparation et sel la constituant.
KR0159540B1 (ko) *	1992-01-21	1998-12-01	김정순	퀴놀론-카복실산의 염 및 그 함유조성물
US5290794A (en) *	1992-10-27	1994-03-01	Warner Lambert Co.	Soluble calcium lactate antibacterial complexes as non-irritating parenteral forms
ES2088742B1 (es)	1994-06-29	1997-03-16	Salvat Lab Sa	Composicion antibiotica de aplicacion otica.
DE19500784A1 (de) *	1995-01-13	1996-07-18	Bayer Ag	Enrofloxacin-Injektions- oder Infusionslösungen
JPH08213881A (ja) *	1995-02-02	1996-08-20	Fujitsu Ltd	周波数制御回路
US5800833A (en) *	1995-02-27	1998-09-01	University Of British Columbia	Method for loading lipid vesicles
ZA964653B (en) *	1995-06-06	1996-12-12	Bayer Ag	Non-irritation non-sensitizing non-ototoxic otic anti-bacterial compositions
US5843930A (en) *	1995-06-06	1998-12-01	Bayer Corporation	Method of treating otitis with ciprofloxacin-hydrocortisone suspension
IT1280428B1 (it) *	1995-07-14	1998-01-20	R R A S R L	Composizione farmaceutica per uso topico
ES2106680B1 (es) *	1995-08-03	1998-07-01	Vita Invest Sa	Composiciones acuosas conteniendo ciprofloxacino y utilizacion y procedimiento correspondientes.
DE19730023A1 (de) *	1997-07-11	1999-01-14	Bayer Ag	Hochreine Ciprofloxacin-Infusion
IN186245B (ja)	1997-09-19	2001-07-14	Ranbaxy Lab Ltd
US6537969B1 (en) *	1997-10-24	2003-03-25	John P. Blass	Nutritional supplement for cerebral metabolic insufficiencies
US6716830B2 (en)	1998-09-30	2004-04-06	Alcon, Inc.	Ophthalmic antibiotic compositions containing moxifloxacin
DE19937116A1 (de) *	1999-08-06	2001-02-08	Bayer Ag	Moxifloxacin Kochsalzformulierung
DE10018783A1 (de) *	2000-04-15	2001-10-25	Fresenius Kabi De Gmbh	Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
MXPA02010497A (es) *	2000-04-24	2003-05-14	Daiichi Seiyaku Co	Preparacion liquida estable.
DE10048510A1 (de) *	2000-09-29	2002-05-16	Fresenius Kabi De Gmbh	Lagerstabile Infusionslösung des Ciprofloxacins mit verringertem Säuregehalt
JP2006151808A (ja) *	2002-12-24	2006-06-15	Dai Ichi Seiyaku Co Ltd	抗菌性水性製剤
US6861422B2 (en) *	2003-02-26	2005-03-01	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
DE102004005186B3 (de) *	2004-02-02	2005-10-13	Krka Tovarna Zdravil, D.D.	Verfahren zur Herstellung von gereinigtem Ciprofloxacin
WO2005123137A2 (en) *	2004-06-18	2005-12-29	Ranbaxy Laboratories Limited	Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride
DE102004029784A1 (de) *	2004-06-21	2006-01-05	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
DE102004033670A1 (de) *	2004-07-09	2006-02-02	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
US7759485B2 (en) *	2004-08-14	2010-07-20	Boehringer Ingelheim International Gmbh	Process for the manufacture of dihydropteridinones
US20060058311A1 (en)	2004-08-14	2006-03-16	Boehringer Ingelheim International Gmbh	Combinations for the treatment of diseases involving cell proliferation
US7728134B2 (en) *	2004-08-14	2010-06-01	Boehringer Ingelheim International Gmbh	Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
US20060035903A1 (en) *	2004-08-14	2006-02-16	Boehringer Ingelheim International Gmbh	Storage stable perfusion solution for dihydropteridinones
US20060074088A1 (en) *	2004-08-14	2006-04-06	Boehringer Ingelheim International Gmbh	Dihydropteridinones for the treatment of cancer diseases
EP1632493A1 (de) *	2004-08-25	2006-03-08	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
EP1630163A1 (de) *	2004-08-25	2006-03-01	Boehringer Ingelheim Pharma GmbH & Co.KG	Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
DE102004054873A1 (de)	2004-11-12	2006-05-18	Bayer Healthcare Ag	Behandlung von Mastitis
DE102004058337A1 (de) *	2004-12-02	2006-06-14	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
AU2005313601B2 (en) *	2004-12-09	2012-05-24	Bayer Intellectual Property Gmbh	Stabilisation of glucocorticoid esters with acids
DE102005055385A1 (de) *	2004-12-09	2006-06-14	Bayer Healthcare Ag	Arzneimittel zur hygienischen Applikation im Ohr
FR2896416B1 (fr) *	2006-01-24	2010-08-13	Vetoquinol	Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
US7439358B2 (en)	2006-02-08	2008-10-21	Boehringer Ingelheim International Gmbh	Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
US20070197548A1 (en) *	2006-02-17	2007-08-23	Murthy Yerramilli V S	Fluoroquinolone compositions
TW200900066A (en) *	2007-03-22	2009-01-01	Daiichi Sankyo Co Ltd	Quinolone medical composition containing alcohols
CA2683939C (en) *	2007-04-13	2012-06-19	Dong Wha Pharmaceutical Co. Ltd.	Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza-spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same
JP5217276B2 (ja) *	2007-07-19	2013-06-19	ニプロ株式会社	注射用抗菌剤の製造方法
EP2185559A1 (en) *	2007-08-03	2010-05-19	Boehringer Ingelheim International GmbH	Crystalline form of a dihydropteridione derivative
WO2010146478A1 (en) *	2009-05-08	2010-12-23	Ranbaxy Laboratories Limited	Parenteral composition comprising a fluoroquinolone compound and a nitroimidazole compound
US8546566B2 (en)	2010-10-12	2013-10-01	Boehringer Ingelheim International Gmbh	Process for manufacturing dihydropteridinones and intermediates thereof
US9358233B2 (en)	2010-11-29	2016-06-07	Boehringer Ingelheim International Gmbh	Method for treating acute myeloid leukemia
US9370535B2 (en)	2011-05-17	2016-06-21	Boehringer Ingelheim International Gmbh	Method for treatment of advanced solid tumors
WO2015011236A1 (en)	2013-07-26	2015-01-29	Boehringer Ingelheim International Gmbh	Treatment of myelodysplastic syndrome
KR101646324B1 (ko) *	2014-03-04	2016-08-05	동화약품주식회사	1-시클로프로필-6-플루오로-7-(8-메톡시이미노-2,6-디아자-스피로[3,4]옥트-6-일)-4-옥소-1,4-디히드로-[1,8]나프티리딘-3-카르복실산 디-아스파르트산염의 수화물 및 이를 포함하는 항균활성 조성물
US9867831B2 (en)	2014-10-01	2018-01-16	Boehringer Ingelheim International Gmbh	Combination treatment of acute myeloid leukemia and myelodysplastic syndrome

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS497419A (ja) *	1972-05-24	1974-01-23
JPS57188515A (en) *	1981-05-13	1982-11-19	Kyoto Yakuhin Kogyo Kk	Stabilized aqueous dopamine preparation
ES8304117A1 (es) *	1981-06-11	1983-02-16	Warner Lambert Co	"un procedimiento para preparar sales de compuestos de naftiridina y quinoleina".
DE3306771A1 (de) *	1983-02-25	1984-08-30	Bayer Ag, 5090 Leverkusen	Chinoloncarbonsaeuren, verfahren zu ihrer herstellung sowie diese enthaltende antibakterielle mittel
DE3333719A1 (de) *	1983-09-17	1985-04-04	Bayer Ag	Loesungen milchsaurer salze von piperazinylchinolon- und piperazinyl-azachinoloncarbonsaeuren

1985
- 1985-10-24 DE DE19853537761 patent/DE3537761A1/de not_active Withdrawn
1986
- 1986-10-09 NO NO864022A patent/NO864022L/no unknown
- 1986-10-13 AT AT86114131T patent/ATE59003T1/de not_active IP Right Cessation
- 1986-10-13 ES ES86114131T patent/ES2021571B3/es not_active Expired - Lifetime
- 1986-10-13 EP EP86114131A patent/EP0219784B1/de not_active Expired - Lifetime
- 1986-10-13 DE DE8686114131T patent/DE3676158D1/de not_active Expired - Lifetime
- 1986-10-21 NZ NZ218016A patent/NZ218016A/xx unknown
- 1986-10-21 UA UA4028324A patent/UA8033A1/uk unknown
- 1986-10-21 AR AR86305638A patent/AR244085A1/es active
- 1986-10-21 SU SU86A patent/SU1487801A3/ru active
- 1986-10-21 PT PT83588A patent/PT83588B/pt unknown
- 1986-10-21 IL IL80380A patent/IL80380A/xx not_active IP Right Cessation
- 1986-10-22 CA CA000521092A patent/CA1282006C/en not_active Expired - Lifetime
- 1986-10-22 FI FI864272A patent/FI84555C/fi not_active IP Right Cessation
- 1986-10-22 DD DD86295467A patent/DD252125A5/de not_active IP Right Cessation
- 1986-10-23 KR KR1019860008863A patent/KR940002664B1/ko not_active Expired - Lifetime
- 1986-10-23 PL PL1986262006A patent/PL152336B1/pl unknown
- 1986-10-23 AU AU64327/86A patent/AU571796B2/en not_active Expired
- 1986-10-23 PH PH34403A patent/PH26419A/en unknown
- 1986-10-23 JP JP61250909A patent/JPH0714879B2/ja not_active Expired - Fee Related
- 1986-10-23 ZA ZA868057A patent/ZA868057B/xx unknown
- 1986-10-23 IE IE280386A patent/IE59385B1/en not_active IP Right Cessation
- 1986-10-23 DK DK198605078A patent/DK175494B1/da not_active IP Right Cessation
- 1986-10-24 HU HU864477A patent/HUT42952A/hu unknown
1989
- 1989-03-29 US US07/329,922 patent/US4957922A/en not_active Expired - Lifetime
1990
- 1990-12-13 GR GR90400940T patent/GR3002544T3/el unknown
1993
- 1993-10-28 HK HK1155/93A patent/HK115593A/xx not_active IP Right Cessation
1994
- 1994-05-06 CY CY172994A patent/CY1729A/xx unknown

Also Published As

Publication number	Publication date
PT83588B (pt)	1989-05-31
DE3537761A1 (de)	1987-04-30
EP0219784B1 (de)	1990-12-12
NO864022L (no)	1987-04-27
EP0219784A2 (de)	1987-04-29
ZA868057B (en)	1987-06-24
KR940002664B1 (ko)	1994-03-28
PL152336B1 (en)	1990-12-31
JPS6299326A (ja)	1987-05-08
ES2021571B3 (es)	1991-11-16
PT83588A (en)	1986-11-01
AU571796B2 (en)	1988-04-21
EP0219784A3 (en)	1987-11-04
IE862803L (en)	1987-04-24
DK507886A (da)	1987-04-25
HUT42952A (en)	1987-09-28
DK175494B1 (da)	2004-11-08
CA1282006C (en)	1991-03-26
DK507886D0 (da)	1986-10-23
UA8033A1 (uk)	1995-12-26
AU6432786A (en)	1987-04-30
US4957922A (en)	1990-09-18
FI84555B (fi)	1991-09-13
NO864022D0 (no)	1986-10-09
GR3002544T3 (en)	1993-01-25
DD252125A5 (de)	1987-12-09
DE3676158D1 (de)	1991-01-24
PL262006A1 (en)	1988-10-13
JPH0714879B2 (ja)	1995-02-22
AR244085A1 (es)	1993-10-29
FI84555C (fi)	1991-12-27
SU1487801A3 (ru)	1989-06-15
NZ218016A (en)	1989-02-24
HK115593A (en)	1993-11-05
FI864272L (fi)	1987-04-25
ATE59003T1 (de)	1990-12-15
IL80380A0 (en)	1987-01-30
FI864272A0 (fi)	1986-10-22
IL80380A (en)	1990-11-29
KR870003786A (ko)	1987-05-04
IE59385B1 (en)	1994-02-23
CY1729A (en)	1994-05-06

Publication	Publication Date	Title
PH26419A (en)	1992-07-15	Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-quinoline-3-carboxyic acid
AU610380B2 (en)	1991-05-16	Novel compounds
JP5548079B2 (ja)	2014-07-16	共溶媒処方物
US10980757B2 (en)	2021-04-20	Ready-to-use tranexamic acid intravenous solution
CZ193098A3 (cs)	1999-05-12	Vodný farmaceutický roztok vhodný pro injekční podávání hostiteli
WO2001078732A1 (de)	2001-10-25	Lagerstabile infusionslösung des ciprofloxacins
US5618841A (en)	1997-04-08	Composition of iodophor teat dip for the prevention of mastitis and a process for using the same
Leite et al.	2021	Antimicrobial activity of polyhexamethylene biguanide nanoparticles against mastitis-causing Staphylococcus aureus
Hoppe et al.	1996	Randomized comparison of two nystatin oral gels with miconazole oral gel for treatment of oral thrush in infants
US20010020029A1 (en)	2001-09-06	New multidose vial formulations for administering endo-N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1-methyl-1H- indazole-3-carboxamide hydrochloride
CA3251195A1 (en)	2023-11-23	COMPOSITIONS CONTAINING VANCOMYCIN
Marx et al.	1988	Cefuroxime axetil
EP2366397A1 (en)	2011-09-21	Intravascular indwelling catheter lock solution containing acetic acid and container containing the same
CN1466457A (zh)	2004-01-07	具有降低的酸含量且贮藏稳定的环丙氟沙星的输注液
CN116549605A (zh)	2023-08-08	一种预防牛乳房炎的药浴液及其制备方法
EP2529728A1 (en)	2012-12-05	Pharmaceutical compositions for the treatment of bacterial infections
US20260053746A1 (en)	2026-02-26	Compositions and methods of use thereof for prevention of mastitis
Occhipinti et al.	1992	Selective Decontamination of the Digestive Tract as an Infection‐Control Measure in Intensive Care Unit Patients
Almazán et al.	2017	PP-025 Implementation of a haemodialysis antibiotic lock catheter therapy protocol and analysis of the results
US3814800A (en)	1974-06-04	Antibacterial composition
Smith	1991	Ofloxacin, a bactericidal antibacterial
CN113304106A (zh)	2021-08-27	一种盐酸克林霉素注射液及其制备方法
KR20050071436A (ko)	2005-07-07	동물용 약제학적 조성물
Taylor et al.	2011	Antimicrobial resistance
Reilly et al.	2009	of the Digestive Tract: Role